Additionally, the 36-month beta value for ZNTL is 1.81. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 6 rating it as “hold,” and 0 rating it as “sell.”
The public float for ZNTL is 54.56M and currently, short sellers hold a 9.31% ratio of that float. The average trading volume of ZNTL on February 05, 2025 was 1.80M shares.
ZNTL) stock’s latest price update
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL)’s stock price has dropped by -2.98 in relation to previous closing price of 1.68. Nevertheless, the company has seen a loss of -32.08% in its stock price over the last five trading days. accessnewswire.com reported 2025-02-04 that NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zentalis Pharmaceuticals, Inc. (“Zentalis Pharmaceuticals, Inc.”) (NASDAQ:ZNTL) concerning possible violations of federal securities laws. Zentalis issued a press release on January 28, 2025, “announc[ing] a restructuring of its business operations and research and development organization to support execution of late-stage development for its WEE1 inhibitor product candidate, azenosertib, and extend its cash runway beyond a data readout from its potentially registration-enabling DENALI Part 2 study, anticipated by the end of 2026.
ZNTL’s Market Performance
ZNTL’s stock has fallen by -32.08% in the past week, with a monthly drop of -45.67% and a quarterly drop of -40.29%. The volatility ratio for the week is 15.31% while the volatility levels for the last 30 days are 11.88% for Zentalis Pharmaceuticals Inc The simple moving average for the last 20 days is -30.29% for ZNTL’s stock, with a simple moving average of -67.77% for the last 200 days.
Analysts’ Opinion of ZNTL
Many brokerage firms have already submitted their reports for ZNTL stocks, with Wedbush repeating the rating for ZNTL by listing it as a “Neutral.” The predicted price for ZNTL in the upcoming period, according to Wedbush is $4 based on the research report published on August 12, 2024 of the previous year 2024.
UBS, on the other hand, stated in their research note that they expect to see ZNTL reach a price target of $5, previously predicting the price at $28. The rating they have provided for ZNTL stocks is “Neutral” according to the report published on June 20th, 2024.
ZNTL Trading at -43.76% from the 50-Day Moving Average
After a stumble in the market that brought ZNTL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.98% of loss for the given period.
Volatility was left at 11.88%, however, over the last 30 days, the volatility rate increased by 15.31%, as shares sank -49.69% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -45.48% lower at present.
During the last 5 trading sessions, ZNTL fell by -32.08%, which changed the moving average for the period of 200-days by -87.18% in comparison to the 20-day moving average, which settled at $2.3382. In addition, Zentalis Pharmaceuticals Inc saw -46.20% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZNTL starting from Skvarka Jan, who purchase 60,000 shares at the price of $1.72 back on Jan 31 ’25. After this action, Skvarka Jan now owns 149,551 shares of Zentalis Pharmaceuticals Inc, valued at $103,446 using the latest closing price.
Walker Luke Nathaniel, the Director of Zentalis Pharmaceuticals Inc, purchase 14,200 shares at $1.76 during a trade that took place back on Jan 31 ’25, which means that Walker Luke Nathaniel is holding 86,681 shares at $24,966 based on the most recent closing price.
Stock Fundamentals for ZNTL
Current profitability levels for the company are sitting at:
- -4.91 for the present operating margin
- 0.98 for the gross margin
The net margin for Zentalis Pharmaceuticals Inc stands at -4.2. The total capital return value is set at -0.53. Equity return is now at value -42.89, with -34.60 for asset returns.
Based on Zentalis Pharmaceuticals Inc (ZNTL), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -4.25.
Currently, EBITDA for the company is -275.5 million with net debt to EBITDA at 0.0. When we switch over and look at the enterprise to sales, we see a ratio of 2.7. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.29.
Conclusion
In conclusion, Zentalis Pharmaceuticals Inc (ZNTL) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
